[DRRX] DURECT Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 195.05 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.28 Change: 0.04 (3.23%)
Ext. hours: Change: 0 (0%)

chart DRRX

Refresh chart

Strongest Trends Summary For DRRX

DRRX is in the medium-term up 208% in 5 months and up 249% in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: DURECT Corporation, a specialty pharmaceutical company, is engaged in the development of pharmaceutical products based on its proprietary drug delivery technology platforms in the United States and internationally. It focuses on the development of various products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, metabolic disorders, cardiovascular disease, and other chronic diseases. The company?s products comprise ALZET product line that consists of osmotic pumps and accessories, which are used for experimental research in mice, rats, and other laboratory animals; and a range of standard and custom biodegradable polymers that are used as raw materials in the pharmaceutical and medical devices under the brand name of LACTEL. Its products also include REMOXY, an oral oxycodone gelatin capsule for chronic pain; POSIDUR, a formulation of bupivacaine for the treatment of post-surgical pain that has completed Phase III clinical study; ELADUR, a Phase

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding137.36 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 4.19% Sales Growth - Q/Q11.81% P/E
P/E To EPS Growth P/S10.91 P/BV12.6 Price/Cash Per Share6.72
Price/Free Cash Flow-13.53 ROA-51.33% ROE-150.97% ROI-65.53%
Current Ratio5.02 Quick Ratio4.5 Long Term Debt/Equity0.62 Debt Ratio0.47
Gross Margin68.52% Operating Margin-122.01% Net Profit Margin-130.66% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities240 K Cash From Investing Activities4.42 M Cash From Operating Activities-5.35 M Gross Profit3.77 M
Net Profit-4.85 M Operating Profit-4.42 M Total Assets45.52 M Total Current Assets36.47 M
Total Current Liabilities7.26 M Total Debt19.84 M Total Liabilities30.04 M Total Revenue4.77 M
Technical Data
High 52 week2.21 Low 52 week0.48 Last close1.85 Last change2.78%
RSI36.19 Average true range0.16 Beta1.38 Volume369.5 K
Simple moving average 20 days-3.34% Simple moving average 50 days8.43% Simple moving average 200 days97.62%
Performance Data
Performance Week1.65% Performance Month5.71% Performance Quart164.29% Performance Half207.87%
Performance Year90.72% Performance Year-to-date282.94% Volatility daily5.23% Volatility weekly11.7%
Volatility monthly23.99% Volatility yearly83.09% Relative Volume282.28% Average Volume1.19 M
New High New Low

News

2019-11-12 08:45:00 | DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in a Late-Breaking Presentation at The Liver Meeting®

2019-11-08 15:27:23 | Edited Transcript of DRRX earnings conference call or presentation 4-Nov-19 9:30pm GMT

2019-11-06 17:47:00 | DURECT to Host Key Opinion Leader Call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results

2019-11-04 16:05:00 | DURECT Corporation Announces Third Quarter 2019 Financial Results and Update of Programs

2019-10-30 08:00:00 | DURECT Corporation to Announce Third Quarter 2019 Financial Results and Provide Business Update on November 4

2019-10-21 10:12:00 | DURECT Announces DUR-928 Phase 2a Alcoholic Hepatitis Study Results Selected for Late-Breaking Oral Presentation at The Liver Meeting® 2019

2019-10-18 10:23:24 | These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year

2019-10-17 16:05:00 | DURECT to Present at Two Upcoming NASH Investor Conferences

2019-10-07 08:00:00 | DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Phase 1b DUR-928 Clinical Trial in NASH

2019-10-02 08:00:00 | DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR® for the Treatment of Post-Surgical Pain

2019-09-26 08:00:00 | DURECT to Present at the 2019 Cantor Fitzgerald Global Health Care Conference

2019-09-18 07:39:49 | The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts

2019-09-17 08:00:00 | DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis

2019-09-09 09:29:00 | DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Utilizing DURECT's SABER® Technology

2019-09-07 12:19:00 | 3 Biotech Stocks That Could Double Your Money

2019-09-06 12:24:00 | Why Durect Stock Is Up Today

2019-09-04 08:00:00 | DURECT to Present at the 21st Annual Rodman and Renshaw Global Investment Conference Sponsored by H.C. Wainwright

2019-08-20 10:00:00 | DRRX: Gilead Agreement, Near-Term Value-Inflection Opportunities Make DRRX Particularly Attractive at Current Valuation

2019-08-02 09:47:12 | Edited Transcript of DRRX earnings conference call or presentation 1-Aug-19 8:30pm GMT

2019-08-01 16:05:00 | DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs

2019-07-29 10:08:38 | Health Care Digest: Kilroy's Oyster Point mystery, helping researchers ditch spreadsheets — and more

2019-07-25 16:30:00 | DURECT Corporation to Announce Second Quarter 2019 Financial Results on August 1

2019-07-22 14:43:01 | Why Durect Corporation Is Soaring Today

2019-07-22 08:00:00 | DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

2019-07-17 08:00:00 | DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIR® Complete Response Letter as a Complete Class 2 Resubmission

2019-06-28 09:15:00 | DRRX: Favorable FDA Decision on POSIMIR Would Likely Mean Significant Upside to Our Model

2019-06-27 08:30:00 | DURECT Announces Submission to FDA of a Full Response to the POSIMIR® Complete Response Letter

2019-06-26 07:19:56 | The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart

2019-06-25 16:30:00 | DURECT Receives Approval from Nasdaq for Transfer of Listing to Nasdaq Capital Market

2019-06-20 08:00:00 | DURECT Announces $15 Million Registered Direct Offering

2019-06-18 08:00:00 | DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis AH in its Ongoing DUR-928 Phase 2a AH Trial

2019-06-11 10:45:16 | Some DURECT NASDAQ:DRRX Shareholders Have Taken A Painful 75% Share Price Drop

2019-05-17 10:50:00 | DRRX: Highly Compelling Initial Ph2a DUR-928 Alcoholic Hepatitis Data. Final Data Later This Year Could Be Value Inflection Event

2019-05-16 16:15:00 | DURECT to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

2019-05-09 12:04:21 | Edited Transcript of DRRX earnings conference call or presentation 8-May-19 12:30pm GMT

2019-05-08 11:40:00 | DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial

2019-05-08 07:53:50 | The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split

2019-05-08 06:30:00 | DURECT Corp. to Host Earnings Call

2019-05-08 05:04:23 | Durect: 1Q Earnings Snapshot

2019-05-07 21:03:00 | DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial

2019-05-07 17:42:00 | DURECT Corporation Announces First Quarter 2019 Financial Results and Update of Programs

2019-05-07 08:20:52 | The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex

2019-05-03 13:26:00 | DURECT Corporation to Present Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial and Report First Quarter 2019 Financial Results

2019-04-25 08:00:00 | DURECT Appoints Two New Board Members

2019-04-22 15:24:24 | DURECT Corporation NASDAQ:DRRX: What's The Analyst Consensus Outlook?

2019-04-01 08:00:00 | DURECT to Present at the H.C. Wainwright Global Life Sciences Conference and Host an Upcoming KOL call on NASH

2019-03-27 08:00:00 | DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis NASH

2019-03-21 08:00:00 | DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis

2019-03-13 16:00:00 | DRRX: DUR-928 Programs Accelerating. Anticipate NASH, Psoriasis Data Later This Year

2019-03-08 22:43:02 | Edited Transcript of DRRX earnings conference call or presentation 7-Mar-19 9:30pm GMT